Cargando…

Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol

Mucopolysaccharidosis VII (MPS VII) is a recessively inherited lysosomal storage disorder caused by β-glucuronidase enzyme deficiency. The disease is characterized by widespread accumulation of non-degraded or partially degraded glycosaminoglycans, leading to cellular and multiple tissue dysfunction...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar, Sudipta, Prasad, Mohit, Datta, Rupak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262814/
https://www.ncbi.nlm.nih.gov/pubmed/30459155
http://dx.doi.org/10.1242/dmm.036954
_version_ 1783375185064230912
author Bar, Sudipta
Prasad, Mohit
Datta, Rupak
author_facet Bar, Sudipta
Prasad, Mohit
Datta, Rupak
author_sort Bar, Sudipta
collection PubMed
description Mucopolysaccharidosis VII (MPS VII) is a recessively inherited lysosomal storage disorder caused by β-glucuronidase enzyme deficiency. The disease is characterized by widespread accumulation of non-degraded or partially degraded glycosaminoglycans, leading to cellular and multiple tissue dysfunctions. The patients exhibit diverse clinical symptoms, and eventually succumb to premature death. The only possible remedy is the recently approved enzyme replacement therapy, which is an expensive, invasive and lifelong treatment procedure. Small-molecule therapeutics for MPS VII have so far remained elusive primarily due to lack of molecular insights into the disease pathogenesis and unavailability of a suitable animal model that can be used for rapid drug screening. To address these issues, we developed a Drosophila model of MPS VII by knocking out the CG2135 gene, the fly β-glucuronidase orthologue. The CG2135(−/−) fly recapitulated cardinal features of MPS VII, such as reduced lifespan, progressive motor impairment and neuropathological abnormalities. Loss of dopaminergic neurons and muscle degeneration due to extensive apoptosis was implicated as the basis of locomotor deficit in this fly. Such hitherto unknown mechanistic links have considerably advanced our understanding of the MPS VII pathophysiology and warrant leveraging this genetically tractable model for deeper enquiry about the disease progression. We were also prompted to test whether phenotypic abnormalities in the CG2135(−/−) fly can be attenuated by resveratrol, a natural polyphenol with potential health benefits. Indeed, resveratrol treatment significantly ameliorated neuromuscular pathology and restored normal motor function in the CG2135(−/−) fly. This intriguing finding merits further preclinical studies for developing an alternative therapy for MPS VII. This article has an associated First Person interview with the first author of the paper.
format Online
Article
Text
id pubmed-6262814
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-62628142018-11-30 Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol Bar, Sudipta Prasad, Mohit Datta, Rupak Dis Model Mech Research Article Mucopolysaccharidosis VII (MPS VII) is a recessively inherited lysosomal storage disorder caused by β-glucuronidase enzyme deficiency. The disease is characterized by widespread accumulation of non-degraded or partially degraded glycosaminoglycans, leading to cellular and multiple tissue dysfunctions. The patients exhibit diverse clinical symptoms, and eventually succumb to premature death. The only possible remedy is the recently approved enzyme replacement therapy, which is an expensive, invasive and lifelong treatment procedure. Small-molecule therapeutics for MPS VII have so far remained elusive primarily due to lack of molecular insights into the disease pathogenesis and unavailability of a suitable animal model that can be used for rapid drug screening. To address these issues, we developed a Drosophila model of MPS VII by knocking out the CG2135 gene, the fly β-glucuronidase orthologue. The CG2135(−/−) fly recapitulated cardinal features of MPS VII, such as reduced lifespan, progressive motor impairment and neuropathological abnormalities. Loss of dopaminergic neurons and muscle degeneration due to extensive apoptosis was implicated as the basis of locomotor deficit in this fly. Such hitherto unknown mechanistic links have considerably advanced our understanding of the MPS VII pathophysiology and warrant leveraging this genetically tractable model for deeper enquiry about the disease progression. We were also prompted to test whether phenotypic abnormalities in the CG2135(−/−) fly can be attenuated by resveratrol, a natural polyphenol with potential health benefits. Indeed, resveratrol treatment significantly ameliorated neuromuscular pathology and restored normal motor function in the CG2135(−/−) fly. This intriguing finding merits further preclinical studies for developing an alternative therapy for MPS VII. This article has an associated First Person interview with the first author of the paper. The Company of Biologists Ltd 2018-11-01 2018-11-20 /pmc/articles/PMC6262814/ /pubmed/30459155 http://dx.doi.org/10.1242/dmm.036954 Text en © 2018. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/4.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Research Article
Bar, Sudipta
Prasad, Mohit
Datta, Rupak
Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol
title Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol
title_full Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol
title_fullStr Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol
title_full_unstemmed Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol
title_short Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol
title_sort neuromuscular degeneration and locomotor deficit in a drosophila model of mucopolysaccharidosis vii is attenuated by treatment with resveratrol
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262814/
https://www.ncbi.nlm.nih.gov/pubmed/30459155
http://dx.doi.org/10.1242/dmm.036954
work_keys_str_mv AT barsudipta neuromusculardegenerationandlocomotordeficitinadrosophilamodelofmucopolysaccharidosisviiisattenuatedbytreatmentwithresveratrol
AT prasadmohit neuromusculardegenerationandlocomotordeficitinadrosophilamodelofmucopolysaccharidosisviiisattenuatedbytreatmentwithresveratrol
AT dattarupak neuromusculardegenerationandlocomotordeficitinadrosophilamodelofmucopolysaccharidosisviiisattenuatedbytreatmentwithresveratrol